VGIT vs XBI
Vanguard Intermediate-Term Treasury ETF vs SPDR S&P Biotech ETF
VGIT$57.26
Vanguard Intermediate-Term Treasury ETF
Intermediate-term US Treasuries (3–10 years).
Expense: 0.03%Yield: 3.97%
XBI$156.41
SPDR S&P Biotech ETF
Equal-weight biotech stocks in the S&P Biotech Index.
Expense: 0.35%Yield: 0.35%
Quick take
- • VGIT has the lower expense ratio at 0.03% vs 0.35% for XBI.
- • VGIT pays a higher dividend yield (3.97%).
Side-by-side metrics
| Metric | VGIT | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.03% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.97% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $49.35B | $10.92B |
YTD return | -0.50% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.81 | 1.01 |
P/E ratio | — | — |
Last price | $57.26 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
VGIT top holdings
Holdings data unavailable for VGIT.
XBI top holdings
Top holdings · XBI
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
Sector breakdown · XBI
Financial Services0.6%
Healthcare99.3%
About VGIT
VGIT (Vanguard Intermediate-Term Treasury ETF) is Intermediate-term US Treasuries (3–10 years). Managed by Vanguard, the fund carries $49.3B in assets under management, an expense ratio of 0.03%, a dividend yield of 3.97%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.